The immunobiology of primary sclerosing cholangitis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease histologically characterized by the presence of intrahepatic and/or extrahepatic biliary duct concentric, obliterative fibrosis, eventually leading to cirrhosis. Approximately 75% of patients with PSC have inflammatory bowel disease. The male predominance of PSC, the lack of a defined, pathogenic autoantigen, and the potential role of the innate immune system suggest that it may be due to dysregulation of immunity rather than a classic autoimmune disease. However, PSC is associated with several classic autoimmune diseases, and the strongest genetic link to PSC identified to date is with the human leukocyte antigen DRB01*03 haplotype. The precise immunopathogenesis of PSC is largely unknown but likely involves activation of the innate immune system by bacterial components delivered to the liver via the portal vein. Induction of adhesion molecules and chemokines leads to the recruitment of intestinal lymphocytes. Bile duct injury results from the sustained inflammation and production of inflammatory cytokines. Biliary strictures may cause further damage as a result of bile stasis and recurrent secondary bacterial cholangitis. Currently, there is no effective therapy for PSC and developing a rational therapeutic strategy demands a better understanding of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toll‐like receptors and adaptor molecules in liver disease: Update†
Seki, E., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.22306 · Cited by 722 · cited 1×
“Similar to the intestinal mucosa, the biliary mucosa expresses multiple TLRs and their expression has been shown to be induced in a variety of liver diseases [ 91 ].”
BackgroundNatural history and prognostic variables in primary sclerosing cholangitis
Farrant, J. M., Hayllar, K. M., Wilkinson, M. L., Karani, J., Portmann, B. C., Westaby, D., & Williams, R. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90673-9 · Cited by 468
Kaplan, G. G., Laupland, K. B., Butzner, D., Urbanski, S. J., & Lee, S. S. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01103.x · Cited by 273 · cited 2×
“84 per 100,000 person-years for women [8].”
BackgroundBergquist, A., Montgomery, S. M., Bahmanyar, S., Olsson, R., Danielsson, Å., Lindgren, S., Prytz, H., Hultcrantz, R., Lööf, L., Sandberg–Gertzén, H., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.016 · Cited by 188
Pohl, J., Ring, A., Stremmel, W., & Stiehl, A. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200601000-00012 · Cited by 111
Cited by
Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management
Eaton, J. E., Talwalkar, J. A., Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.052 · Cited by 436
Pathogenesis of cholestatic liver disease and therapeutic approaches
Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.004 · Cited by 287
Tabibian, J. H., Weeding, E., Jorgensen, R. A., Petz, J. L., Keach, J. C., Talwalkar, J. A., & Lindor, K. D. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12232 · Cited by 267
Hu, G., Gong, A.-Y., Liu, J., Zhou, R., Deng, C., & Chen, X.-M. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00490.2009 · Cited by 63
Nakanuma, Y., Zen, Y., & Portmann, B. C. (2012) · MacSween's Pathology of the Liver · doi:10.1016/b978-0-7020-3398-8.00010-6 · Cited by 56
Metadata
- Authors
- Aron, J. H., & Bowlus, C. L.
- Venue
- Seminars in Immunopathology
- Published
- 2009-05-26
- Volume
- 31
- Issue
- 3
- Pages
- 383-397
- ISSN
- 1863-2297 (ISSN-L)
- 1863-2300
- OpenAlex
- W2135184381
- Cited by
- 111
- References
- 5
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.